- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 newchinabok 的帖子
谢谢.
"The FDA has notified Novartis to put the program on clinical hold," Naoumov said. "The reason is that in the last few months we had a cluster of three patients who developed acute pancreatitis and one last week who died, unfortunately. So, as a result, this is to assess the risk. All these patients had been treated with alisporivir plus PR [pegylated interferon and ribavirin]. We know pancreatitis is on the label of interferon, and we are working to see if adding alisporivir potentiated a known side effect."
“美国食品药物管理局已通知诺华把节目临床搁置,”Naoumov说。 “究其原因是,在过去的几个月里,我们不得不谁开发急性胰腺炎,谁死了,遗憾的是最后一个星期三个病人的集群。所以,作为一个结果,这是评估风险,这些病人经治疗后已与alisporivir加PR [聚乙二醇干扰素和利巴韦林。我们知道胰腺炎是干扰素的标签上,我们正在努力,看看是否添加alisporivir增效已知的副作用。 |
|